Amgen has disclosed ambitions to more than double its 2021 biosimilar revenues by the end of the decade, to roughly $3.5bn-$4bn, as it reiterated that biosimilars were a “very welcome component” of the firm’s largely innovative business.
Amgen: We Expect To Double Biosimilar Sales By 2030
Interchangeability ‘Not Essential’ But A Differentiator; Ustekinumab Studies Continue
Amgen management paid close attention to the company’s biosimilar portfolio and pipeline during several recent calls with investors, including what differentiates the firm from its rivals in the biosimilars space.
More from Biosimilars
• By
The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.
• By
Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.
• By
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
More from Products
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
• By
With discounts reaching up to 90%, ustekinumab biosimilars have eroded originator Stelara’s sales as expected. In its latest quarterly biosimilar market report, Samsung Bioepis also analyzed the latest regulatory steps to streamline biosimilar development.
• By
As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.